B-type natriuretic peptide levels - A new biomarker in the acute coronary syndrome

Katerina Vitlianova

doi:10.14748/ssm.v48i4.1943

B-type natriuretic peptide levels - A new biomarker in the acute coronary syndrome

Katerina Vitlianova

Abstract

Currently, B-type natriuretic peptide (BNP) and N-terminal B-type natriuretic peptide (NT-pro BNP) are recommended as diagnostic and risk stratification tools in relation to heart failure (1). The main stimulus for their secretion is myocardial wall stress in response to myocyte stretch. It is assumed that the elevated BNP levels indicate the degree of the ischemia - induced left ventricular dysfunction in relation to the pathological left ventricle strain and overload in patients with ACSs (2)...

Full Text

References

Darbar D, Davidson NC, Gillpesie N, et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol 1996;78: 284-7.

BrosnanMJ, Clark JS, Jeffs B, et al. Genes encoding atrial and brain natriuretic peptides as candidates for sensitivity to brain ischemia in stroke-prone hypertensive rats. Hypertension. 1999; 33:290-297.

AbbateA, Biondi-Zoccai GG, Bussani R, et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J. Am. Coll. Cardiol. 2003; 41:753-760.

BraunwaldE, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation. 1982; 66:1146-1149.

Omland T, Aakvaag A, Bonarjee VVS, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-9.

GardnerRS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 2003; 24:1735-1743.

Crilley JG, Farrer M. Left ventricular remodeling and brain natriuretic peptide after first myocardial infarction. Heart 2001;86:638-42.

Donald S. C. Ang, Colin F. J. Kong, Michelle P. C. Kao, Allan D. Struthers. Serial Bedside B-type Natriuretic Peptide Strongly Predicts Prognosis in Acute Coronary Syndrome Independent of Echocardiographic Abnormalities. Am Heart J. 2009;158(1):133-140.

StegPG, Dabbous OH, Feldman LJ et al. Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004; 109: 494-499.

Zhao, H., et al., Role of necroptosis in the pathogenesis of solid organ injury. Cell Death Dis, 2015. 6: 1975.

Velazquez EJ, Pfeffer MA. Acute heart failure complicating acute coronary syndromes: a deadly intersection. Circulation. 2004;109:440-442.

WuAH, Parsons L, Every NR et al. Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J. Am. Coll. Cardiol. 2002; 40:1389-1394.

Morrow DA, de Lemos JA, Sabatine MS et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J. Am. Coll. Cardiol. 2003; 41:1264–1272.

Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur. J. Heart Fail. 2004; 6:327–333.

DOI: http://dx.doi.org/10.14748/ssm.v48i4.1943

Array

User Guide